Biovision Technologies, LLC
USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, recorded in grant years 2016–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Biovision ranks #23,989 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 2 technology areas.
- #23,989
- of 49,997 US assignees by volume
- 11th percentile
- by Innovation Score (23.0/100)
- 15.6
- avg claims per patent
- -78%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R23989 · US Corporation #23,989 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 11 grants
- MID-PACK #23,989/49,997
- PHOTO-FINISH Bioprojet
- CPC-NARROW A61B · 2 areas
- INNOV-THIN 23.0/100
- CLAIMS-RICH 15.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -78% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Bioprojet (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Biovision’s 23.0 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Biovision
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Biovision · this assignee 23
Biovision · this assignee
23 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Biovision's Innovation Score is 23.0/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Biovision?
Each dot is one of Biovision’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biovision’s own 15.6 claims/patent is at or below the 16.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Biovision's grants concentrate
Biovision Technologies, LLC is a focused PatentsView assignee: 2 CPC subclasses with 90.9% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2019. By volume, Biovision sits between Bioprojet and BNL Eurolens.
Who files at Biovision's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Bioprojet
Bioprojet
11 patents
- Biosafe
Biosafe SA
11 patents
- Biothera
Biothera Inc.
11 patents
- Biothread
Biothread LLC
11 patents
- Blue Solutions Ca…
Blue Solutions Canada Inc.
11 patents
- Blue Tomato
Blue Tomato, LLC
11 patents
- Bluedot Innovatio…
Bluedot Innovation PTY Ltd.
11 patents
- BNL Eurolens
BNL Eurolens
11 patents
- Biovision ◀
Biovision Technologies, LLC
11 patents
What this shows Biovision holds 11 patents at rank #23,968, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Biovision
By rank, the assignees closest to #23,968 in granted patent volume.
- Bioprojet #23,964 · 11 patents
- Biosafe SA #23,965 · 11 patents
- Biothera Inc. #23,966 · 11 patents
- Biothread LLC #23,967 · 11 patents
- Blue Solutions Canada Inc. #23,969 · 11 patents
- Blue Tomato, LLC #23,970 · 11 patents
- Bluedot Innovation PTY Ltd. #23,971 · 11 patents
- BNL Eurolens #23,972 · 11 patents
Leaders in A61B (Diagnosis)
Other assignees with the most granted patents in Biovision's primary technology class.
- Covidien LP 5,709 in class
- Koniniklijke Philips N.V. 3,414 in class
- Olympus Corporation 2,758 in class
- Boston Scientific Scimed, Inc. 2,362 in class
- Cilag GmbH International 2,063 in class
- Intuitive Surgical Operations, Inc. 1,921 in class
- DePuy Synthes Products, Inc. 1,796 in class
- Ethicon, Inc. 1,762 in class
Biovision's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 4 | 36.4% |
| 2017 | 2 | 18.2% |
| 2018 | 2 | 18.2% |
| 2019 | 1 | 9.1% |
| 2020 | 1 | 9.1% |
| 2021 | 1 | 9.1% |
Which technologies does Biovision Technologies, LLC patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Biovision Technologies, LLC's patent record in context - here's where to go next.
- Biovision Technologies, LLC's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 90.9% of its portfolio - see every assignee active in that class. Explore A61B
- Ranked #23,989 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Biovision Technologies, LLC against Bioprojet, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 23.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.